{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T01:00:16Z","timestamp":1792890016011,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04073-w","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:23:26Z","timestamp":1762521806000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["TAS-102 plus bevacizumab versus TAS-102 alone for metastatic colorectal cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"23","author":[{"given":"Jing","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leitao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"issue":"2","key":"4073_CR1","first-page":"89","volume":"14","author":"P Rawla","year":"2019","unstructured":"Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. Przeglad Gastroenterologiczny. 2019;14(2):89\u2013103.","journal-title":"Przeglad Gastroenterologiczny"},{"issue":"3","key":"4073_CR2","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al. Colorectal cancer statistics, 2020. Cancer J Clin. 2020;70(3):145\u201364.","journal-title":"Cancer J Clin"},{"issue":"8","key":"4073_CR3","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"15","key":"4073_CR4","doi-asserted-by":"publisher","first-page":"3453","DOI":"10.1093\/nar\/26.15.3453","volume":"26","author":"J Momand","year":"1998","unstructured":"Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"20","key":"4073_CR5","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372(20):1909\u201319.","journal-title":"N Engl J Med"},{"issue":"4","key":"4073_CR6","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1200\/JCO.2017.74.3245","volume":"36","author":"J Xu","year":"2018","unstructured":"Xu J, Kim TW, Shen L, Sriuranpong V, Pan H, Xu R, et al. Results of a Randomized, Double-Blind, Placebo-Controlled, phase III trial of Trifluridine\/Tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J Clin Oncology: Official J Am Soc Clin Oncol. 2018;36(4):350\u20138.","journal-title":"J Clin Oncology: Official J Am Soc Clin Oncol"},{"issue":"5","key":"4073_CR7","first-page":"2135","volume":"33","author":"H Tsukihara","year":"2015","unstructured":"Tsukihara H, Nakagawa F, Sakamoto K, Ishida K, Tanaka N, Okabe H, et al. Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts. Oncol Rep. 2015;33(5):2135\u201342.","journal-title":"Oncol Rep"},{"issue":"9","key":"4073_CR8","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/S1470-2045(17)30425-4","volume":"18","author":"Y Kuboki","year":"2017","unstructured":"Kuboki Y, Nishina T, Shinozaki E, Yamazaki K, Shitara K, Okamoto W, et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1\/2 study. Lancet Oncol. 2017;18(9):1172\u201381.","journal-title":"Lancet Oncol"},{"issue":"3","key":"4073_CR9","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","volume":"21","author":"P Pfeiffer","year":"2020","unstructured":"Pfeiffer P, Yilmaz M, M\u00f6ller S, Zitnjak D, Krogh M, Petersen LN, et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(3):412\u201320.","journal-title":"Lancet Oncol"},{"issue":"7","key":"4073_CR10","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"issue":"15","key":"4073_CR11","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA. 2000;283(15):2008\u201312.","journal-title":"JAMA"},{"issue":"4","key":"4073_CR12","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383\u201394.","journal-title":"J Clin Epidemiol"},{"issue":"18","key":"4073_CR13","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","volume":"388","author":"GW Prager","year":"2023","unstructured":"Prager GW, Taieb J, Fakih M, Ciardiello F, Van Cutsem E, Elez E, et al. Trifluridine-Tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med. 2023;388(18):1657\u201367.","journal-title":"N Engl J Med"},{"issue":"1","key":"4073_CR14","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1186\/s12885-019-6475-6","volume":"19","author":"D Kotani","year":"2019","unstructured":"Kotani D, Kuboki Y, Horasawa S, Kaneko A, Nakamura Y, Kawazoe A, et al. Retrospective cohort study of trifluridine\/tipiracil (TAS-102) plus bevacizumab versus trifluridine\/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer. 2019;19(1):1253.","journal-title":"BMC Cancer"},{"issue":"1","key":"4073_CR15","first-page":"76","volume":"22","author":"C Nie","year":"2023","unstructured":"Nie C, Xu W, Chen B, Lv H, Wang J, Liu Y, et al. An exploration of Trifluridine\/Tipiracil monotherapy and in combination with bevacizumab or immune checkpoint inhibitors for patients with metastatic colorectal cancer: A Real-World study. Clin Colorectal Cancer. 2023;22(1):76\u201384.","journal-title":"Clin Colorectal Cancer"},{"issue":"7","key":"4073_CR16","doi-asserted-by":"publisher","first-page":"4157","DOI":"10.21873\/anticanres.14415","volume":"40","author":"M Shibutani","year":"2020","unstructured":"Shibutani M, Nagahara H, Fukuoka T, Iseki Y, Wang EN, Okazaki Y, et al. Combining bevacizumab with Trifluridine\/Thymidine phosphorylase inhibitor improves the survival outcomes regardless of the usage history of bevacizumab in Front-line treatment of patients with metastatic colorectal cancer. Anticancer Res. 2020;40(7):4157\u201363.","journal-title":"Anticancer Res"},{"key":"4073_CR17","doi-asserted-by":"publisher","first-page":"175883592110091","DOI":"10.1177\/17588359211009143","volume":"13","author":"K Chida","year":"2021","unstructured":"Chida K, Kotani D, Nakamura Y, Kawazoe A, Kuboki Y, Shitara K, et al. Efficacy and safety of trifluridine\/tipiracil plus bevacizumab and trifluridine\/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: a retrospective study. Therapeutic Adv Med Oncol. 2021;13:17588359211009143.","journal-title":"Therapeutic Adv Med Oncol"},{"issue":"3","key":"4073_CR18","doi-asserted-by":"publisher","first-page":"e469","DOI":"10.1634\/theoncologist.2019-0541","volume":"25","author":"H Fujii","year":"2020","unstructured":"Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, et al. Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: A retrospective study. Oncologist. 2020;25(3):e469\u201376.","journal-title":"Oncologist"},{"issue":"3","key":"4073_CR19","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s00280-020-04129-6","volume":"86","author":"Y Nose","year":"2020","unstructured":"Nose Y, Kagawa Y, Hata T, Mori R, Kawai K, Naito A, et al. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD\/TPI plus bevacizumab: a retrospective study. Cancer Chemother Pharmacol. 2020;86(3):427\u201333.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"10","key":"4073_CR20","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1007\/s10147-023-02389-9","volume":"28","author":"N Yoshida","year":"2023","unstructured":"Yoshida N, Kuriu Y, Ikeda J, Kudou M, Kirishima T, Okayama T, et al. Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study. Int J Clin Oncol. 2023;28(10):1378\u201387.","journal-title":"Int J Clin Oncol"},{"key":"4073_CR21","doi-asserted-by":"publisher","first-page":"131533","DOI":"10.1016\/j.cej.2021.131533","volume":"425","author":"K Huang","year":"2021","unstructured":"Huang K, Peng D, Yao Z, Xia J, Zhang B, Liu H, et al. Cathodic plasma driven self-assembly of HEAs dendrites by pure single FCC FeCoNiMnCu nanoparticles as high efficient electrocatalysts for OER. Chem Eng J. 2021;425:131533.","journal-title":"Chem Eng J"},{"issue":"7","key":"4073_CR22","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.3390\/cancers12071919","volume":"12","author":"A Ottaiano","year":"2020","unstructured":"Ottaiano A, Normanno N, Facchini S, Cassata A, Nappi A, Romano C, et al. Study of Ras mutations\u2019 prognostic value in metastatic colorectal cancer: STORIA analysis. Cancers (Basel). 2020;12(7):1919.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"4073_CR23","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8(4):299\u2013309.","journal-title":"Cancer Cell"},{"key":"4073_CR24","unstructured":"Shaocheng Z. A real-world study of efficacy and safety analysis of Trifluridine\/Tipiracil combined with bevacizumab as the Late-line treatment of metastatic colorectal cancer. 2024.004388."},{"issue":"1","key":"4073_CR25","doi-asserted-by":"publisher","first-page":"14612","DOI":"10.1038\/s41598-022-18871-9","volume":"12","author":"N Mart\u00ednez-Lago","year":"2022","unstructured":"Mart\u00ednez-Lago N, Chucla TC, De Castro BA, Ponte RV, Rendo CR, Rodriguez MIG, et al. Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine\/tipiracil plus bevacizumab in a real-world setting. Sci Rep. 2022;12(1):14612.","journal-title":"Sci Rep"},{"issue":"6","key":"4073_CR26","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.3892\/or.2014.3487","volume":"32","author":"N Tanaka","year":"2014","unstructured":"Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014;32(6):2319\u201326.","journal-title":"Oncol Rep"},{"issue":"10","key":"4073_CR27","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1634\/theoncologist.2017-0573","volume":"23","author":"C Cremolini","year":"2018","unstructured":"Cremolini C, Rossini D, Martinelli E, Pietrantonio F, Lonardi S, Noventa S, et al. Trifluridine\/Tipiracil (TAS-102) in refractory metastatic colorectal cancer: A multicenter register in the frame of the Italian compassionate use program. Oncologist. 2018;23(10):1178\u201387.","journal-title":"Oncologist"},{"issue":"1","key":"4073_CR28","first-page":"51","volume":"16","author":"S Hamauchi","year":"2017","unstructured":"Hamauchi S, Yamazaki K, Masuishi T, Kito Y, Komori A, Tsushima T, et al. Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102. Clin Colorectal Cancer. 2017;16(1):51\u20137.","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"4073_CR29","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3892\/ol.2021.13044","volume":"22","author":"D Kamiimabeppu","year":"2021","unstructured":"Kamiimabeppu D, Osumi H, Shinozaki E, Ooki A, Wakatsuki T, Yoshino K, et al. Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine\/tipiracil plus bevacizumab. Oncol Lett. 2021;22(5):783.","journal-title":"Oncol Lett"},{"issue":"1","key":"4073_CR30","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.annonc.2019.10.005","volume":"31","author":"T Yoshino","year":"2020","unstructured":"Yoshino T, Cleary JM, Van Cutsem E, Mayer RJ, Ohtsu A, Shinozaki E, et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine\/tipiracil in the RECOURSE and J003 trials. Annals Oncology: Official J Eur Soc Med Oncol. 2020;31(1):88\u201395.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"key":"4073_CR31","doi-asserted-by":"crossref","unstructured":"Schutz FA, Jardim DL, Je Y, Choueiri TK. Haematologic toxicities associated with the addition of bevacizumab in cancer patients. Eur J Cancer (Oxford England: 1990). 2011;47(8):1161\u201374.","DOI":"10.1016\/j.ejca.2011.03.005"},{"key":"4073_CR32","doi-asserted-by":"crossref","unstructured":"Zhu Y, Liu K, Zhu H. TAS-102 with or without bevacizumab treatment for patients with metastatic colorectal cancer: a multi-country cost-effectiveness analysis. Therapeutic Adv Gastroenterol. 2024;17:17562848241284998.","DOI":"10.1177\/17562848241284998"},{"issue":"1","key":"4073_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13561-025-00622-x","volume":"15","author":"M Zhao","year":"2025","unstructured":"Zhao M, Jiang Y, Shao T, Tang W. Safety, efficacy, and cost-effectiveness evaluation of systemic treatments for refractory colorectal cancer: a systematic review and modeling study. Health Econ Rev. 2025;15(1):33.","journal-title":"Health Econ Rev"},{"issue":"1","key":"4073_CR34","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1186\/s12967-024-05184-w","volume":"22","author":"A Ottaiano","year":"2024","unstructured":"Ottaiano A, Santorsola M, Ianniello M, Ceccarelli A, Casillo M, Sabbatino F, et al. Predictive significance of FGFR4 p.G388R polymorphism in metastatic colorectal cancer patients receiving trifluridine\/tipiracil (TAS-102) treatment. J Transl Med. 2024;22(1):379.","journal-title":"J Transl Med"},{"issue":"1","key":"4073_CR35","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1186\/s12885-024-12447-8","volume":"24","author":"FC Aquino de Moraes","year":"2024","unstructured":"Aquino de Moraes FC, Dantas Leite Pess\u00f4a FD, Duarte de Castro Ribeiro CH, Rodrigues Fernandes M, Rodr\u00edguez Burbano RM. Carneiro Dos Santos NP. Trifluridine-tipiracil plus bevacizumab versus trifluridine-tipiracil monotherapy for chemorefractory metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2024;24(1):674.","journal-title":"BMC Cancer"},{"issue":"01","key":"4073_CR36","first-page":"59","volume":"13","author":"Yamei Gao","year":"2021","unstructured":"Gao Yamei, Wang Bin, Wang Yamei, Jia Yitao. Meta-analysis of the efficacy and safety of Trifluridine\/tipiracil combined with bevacizumab in treating refractory metastatic colorectal cancer. Journal of Digestive Oncology. 2021;13(01):59\u201365.","journal-title":"Journal of Digestive Oncology."},{"key":"4073_CR37","doi-asserted-by":"publisher","first-page":"690515","DOI":"10.3389\/fonc.2021.690515","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Qiu H, Chen Y, Wang M, Zhu P, Pan S, et al. A comparison of bevacizumab plus TAS-102 and TAS-102 monotherapy for metastatic colorectal cancer: A systematic review and Meta-Analysis. Front Oncol. 2021;11:690515.","journal-title":"Front Oncol"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04073-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04073-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:23:28Z","timestamp":1762521808000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-04073-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4073"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04073-w","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"420"}}